Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency

Alavi, Seyed Ebrahim; Cabot, Peter J.; Moyle, Peter M.

doi:10.1021/acs.molpharmaceut.9b00308

Cited by 65 publications

(63 citation statements)

References 246 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the present study, PEG was used as a non-toxic polymer [26]. It is used for different purposes due to its aqueous solubility, low immunogenicity, and antigenicity and proper excretion kinetics [26,27].…”

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

This study aims to evaluate the potency of cisplatin (Cispt)-loaded liposome (LCispt) and PEGylated liposome (PLCispt) as therapeutic nanoformulations in the treatment of bladder cancer (BC). Cispt was loaded into liposomes using reverse-phase evaporation method, and the formulations were characterized using dynamic light scattering, scanning electron microscopy, dialysis membrane, and Fourier-transform infrared spectroscopy (FTIR) methods. The results showed that the particles were formed in spherical monodispersed shapes with a nanoscale size (221–274 nm) and controlled drug release profile. The cytotoxicity effects of LCispt and PLCispt were assessed in an in vitro environment, and the results demonstrated that PLCispt caused a 2.4- and 1.9-fold increase in the cytotoxicity effects of Cispt after 24 and 48 h, respectively. The therapeutic and toxicity effects of the formulations were also assessed on BC-bearing rats. The results showed that PLCispt caused a 4.8-fold increase in the drug efficacy (tumor volume of 11 ± 0.5 and 2.3 ± 0.1 mm3 in Cispt and PLCispt receiver rats, respectively) and a 3.3-fold decrease in the toxicity effects of the drug (bodyweight gains of 3% and 10% in Cispt and PLCispt receiver rats, respectively). The results of toxicity were also confirmed by histopathological studies. Overall, this study suggests that the PEGylation of LCispt is a promising approach to achieve a nanoformulation with enhanced anticancer effects and reduced toxicity compared to Cispt for the treatment of BC.

show abstract

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Ghaferi

Asadollahzadeh

Akbarzadeh

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Diabetes is a complex and chronic disease that affects many organs of the body. It increases the risk of various disorders, such as retinopathy, neuropathy, nephropathy, and cardiovascular disease (Alavi, et al., 2019; Preguiça et al., 2020). These disorders are a remarkable cause of increased morbidity and mortality among diabetic people (Eid et al., 2019).…”

Section: Introductionmentioning

confidence: 99%

Camel milk as an alternative treatment regimen for diabetes therapy

Hussain

Wattoo

et al. 2021

Food Science & Nutrition

Self Cite

View full text Add to dashboard Cite

Camel milk is a valuable source of nutrition with a wide range of therapeutic effects. Its unique composition helps to regulate the blood glucose level. The current study is aimed to evaluate the antidiabetic and hepatoprotective effects, as well as lipid profile restoration of camel milk in the diabetic mouse model. This innovative study evaluates the therapeutic effects of camel milk in diabetic mice by simultaneous measurement of blood glucose, HbA1c, ALT, AST, TG, cholesterol, and histopathological studies. The results showed that camel milk has significantly reduced blood glucose, HbA1c (p < .001), aspartate transaminase (AST), alanine transaminase (ALT) (p < .01), triglyceride (TG), and cholesterol (p < .01), compared to that in the diabetic control group. Also, the therapeutic effects of camel milk were completely comparable with the antidiabetic drug glibenclamide. The results of this study suggest that camel milk could be used as a proper alternative treatment regimen for diabetes therapy.

show abstract

“…42 Results of previous studies also demonstrated that PEGylation of liposomes caused an increase in the biological half-life of the encapsulated drug and as a result an increase in drug efficacy. 43,44 In addition, DSPE-PEG-Mal linker was used to conjugate thiolated OX26 to the surface of liposomes as well. Maleimide (Mal) reacts rapidly and efficiently with the thiol group.…”

Section: Discussionmentioning

confidence: 99%

<p>In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin</p>

Ashrafzadeh¹,

Akbarzadeh²,

Heydarinasab³

et al. 2020

IJN

View full text Add to dashboard Cite

Background: Drug delivery systems have demonstrated promising results to cross bloodbrain barrier (BBB) and deliver the loaded therapeutics to the brain tumor. This study aims to utilize the transferrin receptor (TR)-targeted liposomal cisplatin (Cispt) for transporting Cispt across the BBB and deliver Cispt to the brain tumor. Methods: Targeted pegylated liposomal cisplatin (TPL-Cispt) was synthesized using reverse phase evaporation method and thiolated OX26 monoclonal antibody. The formulation was characterized in terms of size, size distribution, zeta potential, drug encapsulation and loading efficiencies, bioactivity, drug release profile, stability and cellular uptake using dynamic light scattering, flame atomic absorption spectroscopy (AAS), ELISA, dialysis membrane, and fluorescence assay. Next, the potency of the formulation to increase the therapeutic effects of Cispt and decrease its toxicity effects was evaluated in the brain tumorbearing rats through measuring the mean survival time (MST), blood factors and histopathological studies. Results: The results showed that TPL-Cispt with a size of 157±8 nm and drug encapsulation efficiency of 24%±1.22 was synthesized, that was biologically active and released Cispt in a slow-controlled manner. The formulation compared to Cispt-loaded PEGylated liposome nanoparticles (PL-Cispt) caused an increase in the cellular uptake by 1.43fold, as well as an increase in the MST of the brain tumor-bearing rats by 1.7-fold compared to the PL-Cispt (P<0.001). TPL-Cispt was potent enough to cause a significant decrease in Cispt toxicity effects (P<0.001). Conclusion: Overall, the results suggest that targeting the Cispt-loaded PEGylated liposome is a promising approach to develop formulation with enhanced efficacy and reduced toxicity for the treatment of brain tumor.

show abstract

Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency

Cited by 65 publications

References 246 publications

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Enhanced Efficacy of PEGylated Liposomal Cisplatin: In Vitro and In Vivo Evaluation

Camel milk as an alternative treatment regimen for diabetes therapy

<p>In vivo Glioblastoma Therapy Using Targeted Liposomal Cisplatin</p>

Contact Info

Product

Resources

About